Navigation Links
United Therapeutics Receives Subpoena From Office of Inspector General
Date:12/9/2013

SILVER SPRING, Md., Dec. 9, 2013 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) announced today that it has received a subpoena from the Office of the Inspector General of the Department of Health and Human Services reflecting an investigation by the United States Department of Justice, principally represented by the United States Attorney's Office in Baltimore. The subpoena requests documents regarding Remodulin® (treprostinil) Injection, Tyvaso® (treprostinil) Inhalation Solution and Adcirca® (tadalafil) Tablets, including the company's marketing practices relating to these products. The company intends to cooperate with the investigation.

About United Therapeutics

United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of unique products to address the unmet medical needs of patients with chronic and life-threatening conditions.

Forward-looking Statements

Statements included in this press release that are not historical in nature are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to certain risks and uncertainties, such as those described in our periodic reports filed with the Securities and Exchange Commission, that could cause actual results to differ materially from anticipated results.  Consequently, such forward-looking statements are qualified by the cautionary statements, cautionary language and risk factors set forth in our periodic reports and documents filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K.  We claim the protection of the safe harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. We are providing this information as of December 9, 2013, and assume no obligation to update or revise the information contained in this press release whether as a result of new information, future events or any other reason. [uthr-g]

REMODULIN and TYVASO are registered trademarks of United Therapeutics Corporation.
ADCIRCA is a registered trademark of Eli Lilly and Company.


'/>"/>
SOURCE United Therapeutics Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Novel Molecular Assay for Patient Screening Detects S. aureus and Newly Emerging MRSA Strains Available in the United States
2. United States Regenerative Medicine Market Analysis to 2016 Featuring Baxter, Medtronic, Stryker & Zimmer
3. Potential Acquisitions and Stock Price Updates - Research Report on BioMarin, Covidien, United Therapeutics, Brookdale, and Seattle Genetics
4. Ten Global Health Organizations United in a Worldwide Campaign to Protect Patients from Fake Medicines
5. Surgical Notes Selected as Preferred Transcription Vendor for United Surgical Partners
6. New Drug Application For Naloxegol Accepted By United States Food And Drug Administration
7. Zevacor Molecular Awards IBA Contract to Build Only Commercial 70 MeV Cyclotron Dedicated to Medical Use in the United States
8. 2013 ISPE Facility of the Year Awards Program Names Novartiss United States Flu Cell Culture Facility as Overall Winner
9. Omnicare (NYSE: OCR) Agrees to Pay United States $120 Million to Settle False Claims Act Suit Alleging Kickbacks
10. Hospira Launches Q Core Sapphire Infusion System in the United States
11. Lamotrigine is One of the Most Commonly Prescribed Drugs Among Newly Diagnosed Bipolar Disorder Patients in the United States
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/21/2017)... -- Faruqi & Faruqi, LLP, a leading national securities law firm, ... KMPH ) of the federal securities class action ... and underwriters of the Company,s April 16, 2015 Initial Public ... The lawsuit has been filed in the ... County on behalf of all those who acquired ...
(Date:1/20/2017)... 2017  Ethicon Endo-Surgery, Inc. announced today ... Inc., a privately held medical device company ... used in operating rooms worldwide. The acquisition ... energy devices with Megadyne,s innovative portfolio of ... in Ethicon,s goal to deliver the most ...
(Date:1/20/2017)... Jan. 20, 2017  Palladian Health, a leading ... the launch of an opioid management program which ... opioids and helps stem the growing tide of ... to treat chronic non-cancer pain (back pain, neck ... and lack of evidence regarding long-term effectiveness. ...
Breaking Medicine Technology:
(Date:1/23/2017)... ... January 23, 2017 , ... Gynecology Associates ... and gynecological services for women of all ages. The staff of ... variety of reproductive services from routine health screenings to diagnosing and treating female ...
(Date:1/23/2017)... ... January 23, 2017 , ... “Life Under Blankets”: an entrancing story about ... “Life Under Blankets” is the creation of published author, Kimberly Mitchell, who earned her ... She went on to pursue a master’s degree in education in the field of ...
(Date:1/22/2017)... FL (PRWEB) , ... January 22, 2017 , ... Zifam ... customers across the world, recently met with big-name retail buyers at the January ECRM ... evidence of efficacy and uses the utmost safety standards in all of its creations ...
(Date:1/21/2017)... ... 2017 , ... Salveo for life, a company that distributes an effervescent lime-flavored ... States as part of its presence to expand its market reach. , Using a ... productions of nasty toxins as a result of drinking alcohol, eliminating those toxins quickly, ...
(Date:1/21/2017)... ... January 21, 2017 , ... Pacifica Graduate Institute’s Alumni Association ... of events for its annual meeting “Coming Home 2017,” an activity-packed weekend of ... 2017” will be held on Friday January 27 through Sunday, January 29, 2017 ...
Breaking Medicine News(10 mins):